<International Circulation>: The RE-LY trial showed that dabigatran significantly reduces the risk of stroke and systemic embolism patients with atrial fibrillation compared to warfarin without increasing the risk of major bleeding. Do you think that now we have enough evidence to replace warfarin with dabigatran？

Prof. Diener: That is only partly true. The low dose of dabigatran was non-inferior to warfarin and the higher dose was superior. In terms of intracranial bleeds and cerebral hemorrhage， both doses were superior to warfarin. I feel that 18，000 patients is enough evidence.